In short. Vitiligo is an autoimmune condition in which the immune system targets the pigment-making cells, leaving sharply defined white patches. It is not an infection, is not contagious, and is not caused by diet. It affects roughly one percent of people worldwide, all skin types, often beginning before age thirty, and it carries real psychological weight.
Key points
- Vitiligo is autoimmune pigment-cell loss, not an infection, and is not caused by diet.
- It affects roughly one percent of people worldwide, across all skin types, often before thirty.
- Pattern predicts behaviour better than any single treatment; site predicts response.
- Active spreading disease is quieted before repigmentation is attempted.
- Face and trunk repigment better than hands, feet, lips and bony areas.
What are the two patterns of vitiligo?
White patches range from a few coin-sized spots to extensive symmetry across the body. Segmental vitiligo follows one body region, often stops spreading, and responds relatively well to treatment. Non-segmental vitiligo, the common symmetric form around the eyes, mouth, hands and body folds, comes and goes in activity over years. Which pattern is present predicts behaviour better than any single treatment.
What else can cause white patches?
Fungal infection lightens skin with fine scale and repigments with antifungal cream. White patches after inflammation, called post-inflammatory hypopigmentation, carry a history of prior rash. Chemical leukoderma from product contact maps to the area of exposure. True vitiligo is usually obvious, but mimics are checked before treatment, and any single enlarging white patch is examined to be certain.
How is vitiligo assessed?
Examination under Wood's lamp reveals early and subclinical vitiligo as bright white. Assessment documents extent as body surface area, activity as new patches and enlarging edges, and the sites involved. Site predicts response: face and trunk repigment well, while hands, feet, lips and bony areas respond poorly. Activity status decides whether the immune activity is quieted first.
Treatment that genuinely repigments
Active disease is controlled before repigmentation is attempted, because repigmenting a moving target fails.
| Situation | Approach | What it can do | Limits |
|---|---|---|---|
| Active spreading disease | Anti-inflammatory creams and short systemic courses | Stop progression | Repigmenting a moving target fails |
| Repigmentation | Topical treatment with narrowband UVB phototherapy, usually twice weekly for months | Repigment responsive sites | Face and trunk respond; hands, feet, lips and bony areas poorly |
| Stable localised patches | Surgical transfer of the patient's own pigment cells | Reach patches phototherapy cannot | Requires stable disease |
| Exceptional near-total, treatment-resistant disease | Depigmentation of remaining pigment | Even tone | Chosen only with extensive counselling |
| Visible face and hands | Medical micropigmentation and cosmetic cover | Camouflage, preserving dignity | Cover only, not repigmentation |
Narrowband UVB is the evidence backbone of repigmentation, and it is given in courses over months rather than as a single session. Camouflage is a legitimate tool, not an admission of failure, and it matters most on the face and hands.
What does the outlook really look like?
Recent-onset vitiligo on the face and trunk often repigments well. Long-standing acral vitiligo, on the hands and feet, resists almost everything. Realistic goals are set at the first visit: control activity, recover what responds, and protect quality of life throughout, including camouflage and support communities when wanted.
Sun protection and when to seek help
White skin has no natural sun protection. Sunburn on vitiligo patches is common and painful, drives more contrast, and phototherapy patients in particular need disciplined protection between sessions. Daily sunscreen is treatment, not optional.
Arrange assessment if:
- New white patches are appearing or existing ones enlarging, because activity is best treated early.
- A white patch is associated with numbness, pain, or colour change in the eye or ear, because rare neurological associations exist.
- Emotional distress is significant, because support is part of treatment, not an afterthought.
Sources
- British Association of Dermatologists: vitiligo patient information
- American Academy of Dermatology: vitiligo diagnosis and management
- Chinese Medical Association, Dermatology Branch: clinical guidance on pigmentary disorders
Internal links
Frequently asked questions
Is vitiligo contagious or caused by diet?
Neither. Vitiligo is autoimmune at its core, with the immune system targeting the pigment-making cells. It is not contagious, not caused by diet, and affects roughly one percent of people worldwide across all skin types, often beginning before the age of thirty.
Can vitiligo be treated?
Active spreading disease is quieted first with anti-inflammatory creams and short systemic courses, because repigmenting a moving target fails. Repigmentation then combines topical treatment with narrowband ultraviolet B phototherapy. Face and trunk repigment well; hands, feet and lips respond poorly.
Will the white patches come back after treatment?
Non-segmental vitiligo comes and goes in activity over years, so results are not permanent. Realistic goals are set at the first visit: control activity, recover what responds, and protect quality of life throughout, including with camouflage where it helps.
Risks & Limitations
- Most chronic skin disease is managed rather than cured, and relapse is expected.
- Treatments typically need 8–12 weeks before response can be judged fairly.
- Topical treatment can cause irritation, dryness, peeling and photosensitivity.
- Systemic therapy may require blood monitoring and carries organ, metabolic and pregnancy risks.
- Isotretinoin in particular requires strict monitoring and pregnancy prevention.
- Pigment change is often slow and may be incomplete.
- No treatment works for everyone, and response cannot be predicted with certainty.
When to Seek Care
- A mole or lesion that changes in size, shape or colour, or starts to bleed, itch or crust.
- Fever with a widespread rash, blistering, or rash involving the eyes, mouth or genitals — seek emergency care.
- Rapidly spreading redness, swelling or pain in the skin.
- Facial swelling or difficulty breathing — possible severe reaction; seek emergency care immediately.
- New or worsening symptoms while taking a monitored medication.
References & Further Reading
- American Academy of Dermatology (AAD) — public and clinical guidance
- World Health Organization (WHO) — skin and infectious disease resources
- Chinese Medical Association, Dermatology Branch — clinical guidance
- Cochrane Library — systematic reviews in dermatology
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.